This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
respiratory tract | 550 |
human rhinovirus | 499 |
respiratory viruses | 465 |
signifi cant | 361 |
identifi ed | 360 |
respiratory syncytial | 335 |
signifi cantly | 333 |
syncytial virus | 325 |
acute respiratory | 309 |
viral infections | 305 |
epithelial cells | 288 |
lower respiratory | 271 |
confl ict | 252 |
respiratory infections | 242 |
hrv infection | 230 |
common cold | 224 |
infl ammatory | 218 |
respiratory illness | 209 |
lung function | 196 |
rhinovirus infection | 191 |
asthma exacerbations | 190 |
young children | 187 |
tract infections | 182 |
infl ammation | 182 |
human rhinoviruses | 179 |
viral infection | 172 |
upper respiratory | 154 |
respiratory viral | 154 |
infl uenza | 152 |
fi rst | 143 |
respiratory symptoms | 140 |
defi ned | 139 |
hrv infections | 134 |
human metapneumovirus | 130 |
respiratory virus | 127 |
asthma exacerbation | 127 |
pulmonary disease | 125 |
gene expression | 125 |
respiratory disease | 124 |
heart rate | 123 |
cohort study | 121 |
airway epithelial | 118 |
fl uid | 118 |
chain reaction | 113 |
polymerase chain | 113 |
rhinovirus infections | 109 |
mean age | 108 |
wa hrv | 108 |
vp vp | 106 |
fi brosis | 105 |
chronic obstructive | 105 |
age years | 105 |
induced asthma | 104 |
risk factors | 104 |
obstructive pulmonary | 103 |
viral rna | 101 |
lung cancer | 98 |
tract infection | 96 |
respiratory infection | 96 |
childhood asthma | 96 |
ifn lambda | 95 |
viral respiratory | 94 |
risk factor | 94 |
virus infection | 93 |
cystic fi | 90 |
lung transplant | 90 |
immune response | 90 |
emergency department | 89 |
disease severity | 89 |
air pollution | 88 |
fi ndings | 88 |
peripheral blood | 87 |
reverse transcription | 87 |
vocal cord | 84 |
doc id | 82 |
influenza virus | 82 |
cord uid | 82 |
acute asthma | 82 |
united states | 79 |
rsv infection | 79 |
hrv species | 79 |
cant differences | 78 |
nucleic acid | 78 |
time pcr | 78 |
determine whether | 78 |
increased risk | 77 |
innate immune | 75 |
cell culture | 75 |
transplant recipients | 74 |
hrv serotypes | 74 |
median age | 74 |
hospitalized children | 74 |
human bocavirus | 73 |
virus infections | 73 |
respiratory pathogens | 71 |
interest nil | 70 |
interest none | 70 |
physical activity | 70 |
pulmonary function | 69 |
allergic rhinitis | 67 |
cantly higher | 67 |
among children | 67 |
infl uence | 66 |
present study | 65 |
viral load | 65 |
healthy controls | 64 |
lung disease | 64 |
acquired pneumonia | 64 |
airway inflammation | 64 |
controlled trial | 63 |
acute exacerbations | 63 |
previous studies | 63 |
cord movement | 63 |
measured using | 62 |
airway narrowing | 62 |
confi rmed | 62 |
children aged | 62 |
otitis media | 62 |
pcr assays | 61 |
experimental rhinovirus | 61 |
bone marrow | 60 |
cell lines | 60 |
birth cohort | 60 |
asthmatic subjects | 60 |
immune responses | 60 |
bronchial epithelial | 59 |
immunocompromised patients | 59 |
antiviral activity | 58 |
stable patients | 58 |
respiratory illnesses | 58 |
airway responsiveness | 58 |
pcr assay | 57 |
upper airway | 57 |
intensive care | 57 |
asm layer | 56 |
statistically signifi | 56 |
results patients | 56 |
pulmonary rehabilitation | 56 |
pleural ultrasound | 56 |
systematic review | 55 |
rna viruses | 55 |
adult patients | 55 |
clinical specimens | 54 |
influenza viruses | 54 |
chest pain | 54 |
severe asthma | 53 |
logistic regression | 53 |
severe respiratory | 53 |
bronchoalveolar lavage | 53 |
molecular epidemiology | 52 |
airfl ow | 52 |
performed using | 52 |
ammatory cytokines | 52 |
smooth muscle | 52 |
age groups | 52 |
previously described | 52 |
cystic fibrosis | 52 |
two groups | 51 |
hrv ent | 51 |
respiratory failure | 51 |
multiplex pcr | 51 |
asm cell | 50 |
attenuated wa | 50 |
cigarette smoke | 50 |
rna polymerase | 50 |
fev fvc | 50 |
ow obstruction | 50 |
spent outdoors | 50 |
clinical features | 50 |
cell responses | 50 |
nomination nil | 49 |
atopic dermatitis | 49 |
phylogenetic analysis | 49 |
month period | 49 |
diffi cult | 48 |
rate variability | 47 |
pregnant women | 47 |
randomized controlled | 47 |
protective immunity | 47 |
type iii | 47 |
lower airway | 46 |
viral pathogens | 46 |
rhinovirus colds | 46 |
mrna expression | 46 |
clinical trials | 46 |
frequently detected | 46 |
children hospitalized | 46 |
crp levels | 46 |
induced sputum | 45 |
fl ow | 45 |
copd patients | 45 |
effi cacy | 45 |
human coronavirus | 45 |
least one | 45 |
ow cytometry | 44 |
medical records | 44 |
hong kong | 44 |
body mass | 44 |
acute rejection | 44 |
immune system | 44 |
hospitalized patients | 44 |
hrv strains | 44 |
respiratory diseases | 44 |
admission rates | 44 |
adhesion molecule | 44 |
clinical samples | 43 |
acute wheezing | 43 |
mean difference | 43 |
significantly higher | 43 |
important role | 43 |
positive samples | 43 |
mass index | 43 |
goblet cell | 43 |
parainfluenza virus | 43 |
study period | 42 |
gord symptoms | 42 |
fev predicted | 42 |
cell transplant | 42 |
action plan | 42 |
hrv detection | 42 |
dl co | 42 |
vo peak | 42 |
airway distensibility | 42 |
gas transfer | 42 |
stem cell | 42 |
hela cells | 42 |
cant difference | 42 |
clinical outcomes | 42 |
asthmatic children | 42 |
cell surface | 42 |
dimensionality reduction | 42 |
respiratory syndrome | 42 |
hyperinfl ation | 42 |
parainfluenza viruses | 42 |
hh pathway | 42 |
vte prophylaxis | 42 |
human enterovirus | 41 |
may reduce | 41 |
nitric oxide | 41 |
rhinovirus serotypes | 41 |
severe acute | 41 |
cell cultures | 41 |
rhinovirus species | 41 |
nucleic acids | 41 |
clinical characteristics | 40 |
acute lower | 40 |
airway epithelium | 40 |
early childhood | 40 |
infectious diseases | 40 |
virulent wa | 40 |
index case | 39 |
nasal secretions | 39 |
culture positive | 39 |
new zealand | 39 |
first years | 39 |
asthma prevalence | 39 |
control group | 38 |
airway infl | 38 |
gnotobiotic pigs | 38 |
leading cause | 38 |
allergic diseases | 38 |
time spent | 38 |
clinical practice | 38 |
acute otitis | 38 |
airway smooth | 38 |
phylogenetic tree | 38 |
viral persistence | 37 |
effi ciency | 37 |
asthma symptoms | 37 |
complete genome | 37 |
prospective study | 37 |
first year | 37 |
mouse model | 37 |
years old | 37 |
intercellular adhesion | 37 |
virus detection | 37 |
internal control | 36 |
clinical severity | 36 |
old children | 36 |
odds ratio | 36 |
tract disease | 36 |
fi broblasts | 36 |
natural history | 36 |
early life | 36 |
clinical data | 36 |
pcr products | 36 |
rotavirus infection | 36 |
atopic subjects | 36 |
reverse transcriptase | 36 |
patients admitted | 36 |
infi ltrates | 36 |
food allergy | 36 |
atopic asthma | 35 |
hypertonic saline | 35 |
methods subjects | 35 |
may also | 35 |
nasopharyngeal aspirates | 35 |
methods retrospective | 35 |
foreign body | 35 |
complication rate | 35 |
clinically signifi | 35 |
time rt | 35 |
recent studies | 35 |
viral replication | 35 |
pleural fl | 35 |
support nhmrc | 35 |
fl ocked | 35 |
allergic disease | 35 |
quantifi ed | 35 |
three patients | 35 |
febrile neutropenia | 35 |
common respiratory | 35 |
northern territory | 35 |
adverse event | 35 |
gene transfer | 35 |
days post | 35 |
lung volume | 35 |
energy expenditure | 35 |
host immune | 35 |
emphysema extent | 35 |
fi nal | 35 |
expression profi | 35 |
birth weight | 34 |
viral etiology | 34 |
persistent asthma | 34 |
wheezing episodes | 34 |
tobacco smoke | 34 |
acute bronchiolitis | 34 |
applied biosystems | 34 |
high prevalence | 34 |
hrv rna | 34 |
type i | 34 |
lymphoid tissues | 34 |
detection rate | 34 |
host cell | 34 |
respiratory distress | 34 |
care unit | 33 |
hrv replication | 33 |
rsv infections | 33 |
prospective cohort | 33 |
lower airways | 33 |
large number | 33 |
viruses detected | 33 |
genetic diversity | 32 |
healthy subjects | 32 |
primary care | 32 |
positive cases | 32 |
throat swabs | 32 |
predictive value | 32 |
acute severe | 32 |
controlled trials | 32 |
sectional study | 32 |
diagnosed asthma | 32 |
asthma attacks | 32 |
antiviral agents | 32 |
acute exacerbation | 32 |
preliminary results | 31 |
analysed using | 31 |
chronic cough | 31 |
inhaled corticosteroids | 31 |
human respiratory | 31 |
retrospective review | 31 |
amino acid | 31 |
particulate matter | 31 |
allergen exposure | 31 |
health care | 31 |
also showed | 31 |
viral detection | 31 |
mg ml | 31 |
public health | 31 |
lamina propria | 31 |
human airway | 31 |
hospital admissions | 31 |
active site | 31 |
molecular methods | 31 |
table shows | 30 |
hrv types | 30 |
respiratory samples | 30 |
one subject | 30 |
children born | 30 |
human lung | 30 |
chronic respiratory | 30 |
hospital admission | 30 |
vp sequences | 30 |
receptor expression | 30 |
nutritional status | 30 |
significant difference | 30 |
viral co | 30 |
identifi cation | 30 |
nasal washings | 30 |
strongly associated | 30 |
statistically significant | 30 |
cell proliferation | 30 |
igg asc | 30 |
nucleotide sequence | 30 |
commonly used | 30 |
quantifi cation | 29 |
prototype strains | 29 |
modifi ed | 29 |
pilot study | 29 |
tidal breathing | 29 |
may contribute | 29 |
health study | 29 |
cohort studies | 29 |
time points | 29 |
rna synthesis | 29 |
positive results | 29 |
hrv respiratory | 29 |
common colds | 29 |
febrile hrv | 29 |
coding region | 29 |
parainfl uenza | 29 |
high risk | 29 |
cantly different | 29 |
current asthma | 29 |
small airways | 29 |
acute lung | 29 |
months later | 29 |
symptom scores | 29 |
sore throat | 29 |
significant differences | 29 |
immune defect | 29 |
epithelial cell | 29 |
bp deletion | 28 |
body inhalation | 28 |
olic acid | 28 |
stranded rna | 28 |
pacifi ca | 28 |
cell parameters | 28 |
second test | 28 |
wheezing children | 28 |
lung infl | 28 |
metal screws | 28 |
prince charles | 28 |
ct larynx | 28 |
neutrophilic asthma | 28 |
tissue culture | 28 |
charles hospital | 28 |
appropriate vte | 28 |
acute cough | 28 |
exible bronchoscopy | 28 |
lc sprint | 28 |
without bpd | 28 |
ocked swabs | 28 |
antibiotic use | 28 |
side effects | 28 |
function tests | 28 |
nasal fl | 28 |
time reverse | 28 |
increased airway | 28 |
infection may | 28 |
methods patients | 28 |
may play | 28 |
refl ux | 28 |
born preterm | 28 |
ww use | 28 |
fl exible | 28 |
ammatory mediators | 28 |
haematological malignancy | 28 |
virus isolation | 28 |
fi bre | 28 |
retrospective audit | 28 |
viral culture | 28 |
null mefs | 28 |
ed using | 28 |
pleural effusions | 28 |
minute walk | 28 |
pulmonary infi | 28 |
sprint junior | 28 |
determined using | 28 |
airway dysfunction | 28 |
elastic recoil | 28 |
specific iga | 28 |
initial phase | 28 |
may provide | 27 |
cell transplantation | 27 |
samples collected | 27 |
using real | 27 |
mononuclear cells | 27 |
clinical symptoms | 27 |
host response | 27 |
vp region | 27 |
age group | 27 |
preschool children | 27 |
nucleotide divergence | 27 |
inoculated pigs | 27 |
rhinovirus genotype | 27 |
protein expression | 27 |
pigs inoculated | 27 |
surface receptor | 27 |
based study | 26 |
standard deviation | 26 |
blood mononuclear | 26 |
antibody responses | 26 |
adverse events | 26 |
without asthma | 26 |
carbon monoxide | 26 |
hct recipients | 26 |
recurrent wheezing | 26 |
virus type | 26 |
demographic data | 26 |
nested pcr | 26 |
broad spectrum | 26 |
cold symptoms | 26 |
like illness | 26 |
virus replication | 26 |
control subjects | 26 |
sequence analysis | 26 |
acid sequence | 26 |
older children | 26 |
molecular typing | 25 |
specific ige | 25 |
closely related | 25 |
positive result | 25 |
cold virus | 25 |
detection methods | 25 |
control study | 25 |
asthma control | 25 |
airways disease | 25 |
severe disease | 25 |
common cause | 25 |
untranslated region | 25 |
data collected | 25 |
mean duration | 25 |
human coronaviruses | 25 |
allergic sensitization | 25 |
minor group | 25 |
asthmatic patients | 25 |
dust mite | 25 |
time series | 25 |
hematopoietic cell | 25 |
year old | 25 |
antibiotic therapy | 25 |
disease control | 25 |
severe pneumonia | 25 |
virus detected | 25 |
year period | 25 |
house dust | 24 |
chronic disease | 24 |
barrier function | 24 |
study aimed | 24 |
igg memory | 24 |
induced wheezing | 24 |
risk score | 24 |
studies using | 24 |
geometric mean | 24 |
adverse effects | 24 |
informed consent | 24 |
hrv positive | 24 |
dependent rna | 24 |
risk children | 24 |
tested positive | 24 |
diagnostic procedures | 24 |
highly conserved | 24 |
increasing age | 24 |
major cause | 24 |
nasal washes | 24 |
real time | 24 |
human cell | 24 |
test results | 24 |
may cause | 24 |
infected cells | 24 |
recent study | 24 |
infections among | 24 |
healthy children | 24 |
data collection | 24 |
preterm birth | 24 |
pediatric patients | 24 |
odds ratios | 24 |
rhinovirus type | 24 |
infl uenced | 24 |
results suggest | 24 |
human enteroviruses | 24 |
airway remodeling | 24 |
tertiary hospital | 24 |
western blot | 23 |
new york | 23 |
infected mice | 23 |
limited data | 23 |
airway obstruction | 23 |
rhinovirus rna | 23 |
proinfl ammatory | 23 |
oxidative stress | 23 |
general population | 23 |
success rate | 23 |
rsv bronchiolitis | 23 |
genome sequences | 23 |
respiratory secretions | 23 |
regression analysis | 23 |
one patient | 23 |
bacterial infections | 23 |
ent infections | 23 |
viral loads | 23 |
cantly lower | 23 |
severe copd | 23 |
three age | 23 |
induced neutrophilic | 23 |
airway hyperresponsiveness | 23 |
reverse transcribed | 23 |
clinical isolates | 23 |
strand rna | 23 |
study showed | 23 |
oxygen supplementation | 23 |
previously shown | 23 |
stable asthma | 23 |
retrospective case | 23 |
cytokine release | 22 |
secondary outcomes | 22 |
consecutive patients | 22 |
general medical | 22 |
primary outcome | 22 |
fifty percent | 22 |
three hospitals | 22 |
severe persistent | 22 |
simultaneous detection | 22 |
described previously | 22 |
developing countries | 22 |
mechanical ventilation | 22 |
one study | 22 |
cell migration | 22 |
children recruited | 22 |
oxygen use | 22 |
also found | 22 |
data suggest | 22 |
significantly associated | 22 |
mean fev | 22 |
small number | 22 |
healthy population | 22 |
copd subjects | 22 |
lung volumes | 22 |
baseline airway | 22 |
case reports | 22 |
situ hybridization | 22 |
primer pairs | 22 |
ammatory response | 22 |
eosinophilic asthma | 22 |
profi le | 22 |
based amplification | 22 |
control antigen | 22 |
lung tissue | 22 |
stable copd | 22 |
case series | 22 |
dietary intakes | 22 |
sputum cultures | 22 |
noncoding region | 22 |
patients attending | 22 |
interstitial pneumonia | 22 |
benefi ts | 22 |
invasive ventilation | 22 |
experimentally induced | 21 |
version posted | 21 |
rhinovirus prototype | 21 |
forced oscillation | 21 |
cant increase | 21 |
tj proteins | 21 |
fi lter | 21 |
respiratory physicians | 21 |
extended family | 21 |
risk interventions | 21 |
lpc lv | 21 |
elevated rvsp | 21 |
niv service | 21 |
viral genome | 21 |
experimental hrv | 21 |
transmural pressure | 21 |
retrospective study | 21 |
spontaneous pneumothorax | 21 |
eb vs | 21 |
caudal lobe | 21 |
neutrophilic infl | 21 |
three months | 21 |
factors associated | 21 |
seven patients | 21 |
cell volume | 21 |
lung resection | 21 |
cantly less | 21 |
cpap implementation | 21 |
pulmonary tuberculosis | 21 |
eflow rapid | 21 |
neutrophilic aad | 21 |
multiplex rt | 21 |
bore icc | 21 |
newly identified | 21 |
inhaler technique | 21 |
pathway genes | 21 |
exercise tolerance | 21 |
volume density | 21 |
nebulization time | 21 |
longitudinal health | 21 |
ultrasound marking | 21 |
calcium chelators | 21 |
clinic population | 21 |
colistin use | 21 |
tasmanian longitudinal | 21 |
implementation sleep | 21 |
granted medrxiv | 21 |
whole airway | 21 |
rst exposure | 21 |
mrc grade | 21 |
volume fractions | 21 |
hospitalized infants | 21 |
nasal swabs | 21 |
relieves dyspnoea | 21 |
previous study | 21 |
total adr | 21 |
infectious virus | 21 |
oscillation technique | 21 |
apoptotic cells | 21 |
citrate increased | 21 |
thoracic medicine | 21 |
glucose tolerance | 21 |
bronchoscopy plus | 21 |
results participants | 21 |
national surveillance | 21 |
bronchopulmonary dysplasia | 21 |
causative agents | 21 |
mouse trachea | 21 |
written action | 21 |
aboriginal children | 21 |
step pcr | 21 |
received lpc | 21 |
transplant rejection | 21 |
mw achieved | 21 |
proportion immune | 21 |
ammatory phenotypes | 21 |
neutrophil proteases | 21 |
epidemiological studies | 21 |
new bpd | 21 |
ultrasound training | 21 |
author funder | 21 |
native lung | 21 |
service model | 21 |
overall survival | 21 |
standard exercise | 21 |
increased ar | 21 |
significant increase | 21 |
cant correlation | 21 |
adl score | 21 |
sleep study | 21 |
following stimulation | 21 |
palliative care | 21 |
transplant patients | 21 |
positive upa | 21 |
viruses including | 21 |
normal cxr | 21 |
city hospital | 21 |
months post | 21 |
reduced dlco | 21 |
best guess | 21 |
virus bronchiolitis | 21 |
lower fi | 21 |
increased susceptibility | 21 |
viral pathogen | 21 |
translation effi | 21 |
pulmonary side | 21 |
niv relieves | 21 |
inhaled therapy | 21 |
cycle ergometer | 21 |
daily living | 21 |
image guidance | 21 |
oxygen saturation | 21 |
ep receptors | 21 |
cough rate | 21 |
maternal asthma | 21 |
ventilation distribution | 21 |
cytokine response | 21 |
ep receptor | 21 |
positive specimens | 21 |
capsule endoscope | 21 |
well established | 21 |
ultrafi ne | 21 |
cdna synthesis | 21 |
diffusing capacity | 21 |
asthma foundation | 21 |
phase iii | 21 |
stage nsclc | 21 |
reproductive factors | 21 |
copyright holder | 21 |
volume fraction | 21 |
like cells | 21 |
tc groups | 21 |
key hh | 21 |
aeroneb go | 21 |
pleural infection | 21 |
total lung | 21 |
inflammatory response | 21 |
symptom control | 21 |
common symptom | 21 |
cell pro | 21 |
plus bal | 21 |
treatment options | 20 |
multiple viruses | 20 |
well known | 20 |
different viruses | 20 |
clinical impact | 20 |
clinical manifestations | 20 |
rv infection | 20 |
surveillance data | 20 |
thrombocytosis group | 20 |
term care | 20 |
agarose gel | 20 |
asthma patients | 20 |
new rhinovirus | 20 |
exhaled nitric | 20 |
positive patients | 20 |
acute viral | 20 |
major group | 20 |
machine learning | 20 |
prevalence rates | 20 |
airway disease | 20 |
obstructive lung | 20 |
clinical disease | 20 |
table iii | 20 |
various respiratory | 20 |
protease inhibitors | 20 |
overall prevalence | 20 |
adjusted odds | 20 |
allergic airway | 20 |
bacterial pathogens | 20 |
symptom severity | 19 |
chest tightness | 19 |
associated wheezing | 19 |
numbering system | 19 |
hospital stay | 19 |
chronic lung | 19 |
younger age | 19 |
lung diseases | 19 |
community acquired | 19 |
human parainfluenza | 19 |
mechanisms underlying | 19 |
serum ige | 19 |
rhinovirus illnesses | 19 |
adult mice | 19 |
monoclonal antibody | 19 |
international study | 19 |
necrosis factor | 19 |
recently identified | 19 |
capsid protein | 19 |
nucleotide sequences | 19 |
protein levels | 19 |
positive test | 19 |
epidemiologic studies | 19 |
ige levels | 19 |
febrile respiratory | 19 |
children less | 19 |
highly prevalent | 19 |
ibs method | 19 |
also detected | 19 |
study population | 19 |
similar results | 19 |
nasal samples | 19 |
respiratory function | 19 |
based studies | 19 |
rate dynamics | 19 |
prospective studies | 19 |
two years | 19 |
molecular assays | 19 |
defi ne | 19 |
sputum samples | 18 |
chronic asthma | 18 |
children admitted | 18 |
computed tomography | 18 |
may occur | 18 |
using standard | 18 |
tumor necrosis | 18 |
sample size | 18 |
respiratory health | 18 |
elispot assay | 18 |
clinical trial | 18 |
hematopoietic stem | 18 |
outdoor air | 18 |
new hrv | 18 |
virus shedding | 18 |
study involving | 18 |
oral corticosteroids | 18 |
asthma attack | 18 |
cell counts | 18 |
united kingdom | 18 |
viral capsid | 18 |
primary prevention | 18 |
iga asc | 18 |
marrow transplant | 18 |
older people | 18 |
clinical course | 18 |
age children | 18 |
pcr primers | 18 |
like receptor | 18 |
iii ifn | 18 |
results show | 18 |
wheezing illness | 18 |
novel hrv | 18 |
refl ect | 18 |
assessed using | 18 |
clinically relevant | 18 |
study suggests | 18 |
smoking status | 18 |
previously reported | 18 |
among infants | 18 |
birth outcomes | 18 |
hrv isolates | 18 |
health survey | 18 |
recent years | 18 |
respiratory exacerbations | 18 |
bronchial hyperresponsiveness | 18 |
improved detection | 18 |
infected patients | 18 |
randomness index | 18 |
natural products | 18 |
made available | 18 |
significantly different | 18 |
study shows | 18 |
new method | 18 |
reduced airway | 18 |
nasal epithelial | 17 |
previously unrecognized | 17 |
adverse birth | 17 |
using polymerase | 17 |
viruses associated | 17 |
single virus | 17 |
detection rates | 17 |
rhinovirus serotype | 17 |
analyzed using | 17 |
new treatment | 17 |
different hrv | 17 |
host cells | 17 |
molecular detection | 17 |
forced expiratory | 17 |
inflammatory cells | 17 |
hrv group | 17 |
airway cells | 17 |
patient age | 17 |
respiratory specimens | 17 |
three different | 17 |
pain patients | 17 |
detected viruses | 17 |
forward primer | 17 |
exact test | 17 |
medication use | 17 |
hrv type | 17 |
genomic rna | 17 |
disease pathogenesis | 17 |
middle ear | 17 |
rotavirus vaccines | 17 |
tract symptoms | 17 |
hrv detected | 17 |
expiratory volume | 17 |
significantly lower | 17 |
distinct human | 17 |
hrv infected | 17 |
vp gene | 17 |
clinical signs | 17 |
rhinovirus replication | 17 |
dna sequencing | 17 |
less likely | 17 |
reverse primer | 17 |
wilcoxon signed | 17 |
molecular techniques | 17 |
syndrome coronavirus | 17 |
york state | 17 |
posted july | 17 |
young adults | 17 |
platelet counts | 17 |
myocardial infarction | 17 |
whole blood | 17 |
nk cells | 17 |
metapneumovirus infection | 17 |
pcr amplification | 17 |
atypical bacteria | 17 |
health status | 17 |
room temperature | 17 |
family history | 17 |
dietary intake | 17 |
statistical analysis | 17 |
infection control | 17 |
smoking cessation | 17 |
also collected | 17 |
classifi ed | 17 |
world health | 17 |
table ii | 17 |
immunosorbent assay | 17 |
daily symptom | 17 |
aged children | 17 |
tract illness | 17 |
large airway | 16 |
immunosuppressed patients | 16 |
may suggest | 16 |
care facilities | 16 |
pulmonary exacerbation | 16 |
asthma rhinovirus | 16 |
results showed | 16 |
current study | 16 |
also assessed | 16 |
newly identifi | 16 |
positively associated | 16 |
median time | 16 |
asthma hospitalizations | 16 |
multiplex reverse | 16 |
copd exacerbations | 16 |
learning dimensionality | 16 |
predictive values | 16 |
asthma phenotypes | 16 |
rna genome | 16 |
used prior | 16 |
confi dence | 16 |
risk stratification | 16 |
asthmatic epithelium | 16 |
bronchial asthma | 16 |
oral prednisolone | 16 |
future studies | 16 |
dendritic cells | 16 |
pediatric outpatients | 16 |
evidence indicates | 16 |
density lipoprotein | 16 |
higher rates | 16 |
preterm children | 16 |
written informed | 16 |
steroid treatment | 16 |
microbiological yield | 16 |
patients presenting | 16 |
inhibits rhinovirus | 16 |
intestinal iga | 16 |
airway diseases | 16 |
cumulative incidence | 16 |
conventional methods | 16 |
virus types | 16 |
rna virus | 16 |
air pollutants | 16 |
increased likelihood | 16 |
better understanding | 16 |
cell type | 16 |
healthy volunteers | 16 |
several studies | 16 |
increased numbers | 16 |
previous reports | 16 |
reduced expression | 16 |
tlr activation | 16 |
pcr product | 16 |
asthmatic airway | 16 |
significantly increased | 16 |
diagnostic yield | 16 |
two methods | 16 |
adult population | 16 |
viral nucleic | 16 |
pseudomonas aeruginosa | 16 |
clinical outcome | 16 |
novel group | 16 |
another study | 16 |
allergen challenge | 16 |
preliminary data | 16 |
low birth | 16 |
wide range | 16 |
symptom diaries | 16 |
human rotavirus | 16 |
new strains | 16 |
three cases | 16 |
pg ml | 16 |
detected virus | 16 |
international license | 16 |
nucleotide identity | 16 |
remain unclear | 16 |
respiratory system | 16 |
asthma development | 15 |
reactive protein | 15 |
upper airways | 15 |
last months | 15 |
air quality | 15 |
short course | 15 |
contact tracing | 15 |
chest physicians | 15 |
sense rna | 15 |
less successful | 15 |
gnotobiotic pig | 15 |
may help | 15 |
asthmatic compared | 15 |
patient group | 15 |
predicted fev | 15 |
compared using | 15 |
mouth disease | 15 |
interstitial lung | 15 |
atopic sensitization | 15 |
cellular receptor | 15 |
childhood wheezing | 15 |
refl ex | 15 |
pleural effusion | 15 |
healthy non | 15 |
important cause | 15 |
cantly improved | 15 |
recognition molecules | 15 |
rna replication | 15 |
research project | 15 |
molecular epidemiological | 15 |
effi cient | 15 |
tissue samples | 15 |
ml pgg | 15 |
function testing | 15 |
per year | 15 |
sampling method | 15 |
middle east | 15 |
nasba assay | 15 |
infections may | 15 |
bead array | 15 |
medical staff | 15 |
twice daily | 15 |
blood pressure | 15 |
heart failure | 15 |
lipoprotein receptor | 15 |
comprehensive detection | 15 |
often associated | 15 |
severe illness | 15 |
influenza vaccine | 15 |
specific primers | 15 |
severe bronchiolitis | 15 |
also signifi | 15 |
dence interval | 15 |
genome sequence | 15 |
available data | 15 |
reference strains | 15 |
health issue | 15 |
normal spirometry | 15 |
subjects underwent | 15 |
sample entropy | 15 |
bronchial responsiveness | 15 |
expression levels | 15 |
sequence alignment | 15 |
gestational age | 15 |
cytopathic effect | 15 |
total number | 15 |
quantifi able | 15 |
gradient centrifugation | 15 |
year follow | 15 |
infl uenzae | 15 |
illness episodes | 15 |
study aims | 15 |
death worldwide | 15 |
among hospitalized | 15 |
experimental infection | 15 |
cell degranulation | 15 |
complications occurred | 15 |
drug delivery | 15 |
ethics committee | 15 |
single dose | 15 |
infl uences | 15 |
early adulthood | 15 |
profi les | 15 |
another virus | 15 |
lung epithelial | 15 |
airway hyper | 15 |
bovine serum | 15 |
amplifi cation | 15 |
environmental factors | 15 |
saline challenge | 15 |
respiratory medicine | 15 |
mucosal immune | 15 |
ml pa | 15 |
hay fever | 15 |
patient demographics | 15 |
asc responses | 15 |
cough refl | 15 |
animal models | 15 |
negative predictive | 15 |
relatively common | 15 |
transcription factor | 15 |
negative result | 15 |
antibody titres | 15 |
novel human | 15 |
greater variability | 15 |
life cycle | 15 |
hrv pcr | 15 |
strong positive | 15 |
stable state | 15 |
standard curve | 15 |
antiviral therapy | 15 |
remains high | 14 |
dynamic hyperinfl | 14 |
di amplitude | 14 |
bore iccs | 14 |
activity levels | 14 |
half reported | 14 |
performed two | 14 |
pna positive | 14 |
laryngeal behaviour | 14 |
copd underwent | 14 |
glycation end | 14 |
mrna stability | 14 |
extended culture | 14 |
community hospitals | 14 |
cell number | 14 |
sputum testing | 14 |
two antibodies | 14 |
indoor air | 14 |
rst time | 14 |
unilateral tp | 14 |
cough duration | 14 |
starting using | 14 |
normal vocal | 14 |
number concentrations | 14 |
prospectively followed | 14 |
clinical pharmacist | 14 |
pulmonary tb | 14 |
pandemic specimens | 14 |
lung elastic | 14 |
results vocal | 14 |
diagnostic sampling | 14 |
dicarboxylic acids | 14 |
na absorption | 14 |
common causes | 14 |
pilot data | 14 |
cant bleeding | 14 |
ranks test | 14 |
luciferase activity | 14 |
uenza alone | 14 |
bone mineral | 14 |
unexplained variation | 14 |
maximal response | 14 |
specifi ed | 14 |
function laboratory | 14 |
ca families | 14 |
provides additional | 14 |
cpap via | 14 |
deep inspiration | 14 |
alveolar macrophages | 14 |
allergen challenges | 14 |
major source | 14 |
end products | 14 |
fold increase | 14 |
immediate bleeding | 14 |
results thirty | 14 |
methods consecutive | 14 |
exercise session | 14 |
increasing frequency | 14 |
mesenchymal markers | 14 |
advanced glycation | 14 |
three groups | 14 |
microbiological diagnosis | 14 |
hours spent | 14 |
rm anova | 14 |
infected infants | 14 |
clearance rates | 14 |
selected consisting | 14 |
nucleotidyl transfer | 14 |
upa testing | 14 |
test repetition | 14 |
respiratory ward | 14 |
novel imaging | 14 |
whether eicosanoids | 14 |
radiology department | 14 |
reduced dynamic | 14 |
primary cultures | 14 |
virus positive | 14 |
airway pretreatment | 14 |
later age | 14 |
dyspnoea scale | 14 |
bronchodilator response | 14 |
regression models | 14 |
negative exacerbations | 14 |
retrieval team | 14 |
macrophage function | 14 |
barwon health | 14 |
medical conditions | 14 |
smoke exposure | 14 |
patients managed | 14 |
streptococcus pneumoniae | 14 |
service providers | 14 |
ipaq ee | 14 |
subjects subsequently | 14 |
plasma cells | 14 |
induces goblet | 14 |
term colistin | 14 |
dependent airways | 14 |
clinical audit | 14 |
major city | 14 |
novel mask | 14 |
following admission | 14 |
treat asthma | 14 |
thick sections | 14 |
improved signifi | 14 |
latent tuberculosis | 14 |
actual mw | 14 |
vp sequence | 14 |
royal adelaide | 14 |
average length | 14 |
ion transport | 14 |
health committee | 14 |
pathway proteins | 14 |
iet cytokines | 14 |
lung luminescence | 14 |
cellular migration | 14 |
iet cells | 14 |
lobar pneumonia | 14 |
methods participants | 14 |
brosis bronchiectasis | 14 |
spearman correlations | 14 |
airway sections | 14 |
inhaled metal | 14 |
cells infected | 14 |
leak compared | 14 |
using pcr | 14 |
skin test | 14 |
colistin patients | 14 |
sheep model | 14 |
isolated reduction | 14 |
learning effect | 14 |
normal mice | 14 |
remains unclear | 14 |
methods using | 14 |
stable lung | 14 |
cellular infl | 14 |
ambient ultrafi | 14 |
will inform | 14 |
lung mechanics | 14 |
steps recorded | 14 |
patient groups | 14 |
base call | 14 |
less stable | 14 |
poorly understood | 14 |
examine laryngeal | 14 |
genetic cluster | 14 |
action plans | 14 |
obstructive sleep | 14 |
procedures performed | 14 |
isolated human | 14 |
bre intake | 14 |
results subjects | 14 |
equally effective | 14 |
remaining procedures | 14 |
multiparameter fl | 14 |
supine posture | 14 |
cc tlc | 14 |
pb group | 14 |
model provides | 14 |
nasal lavage | 14 |
causative agent | 14 |
high frequency | 14 |
myositis antibodies | 14 |
mean ages | 14 |
onset ar | 14 |
enriched sub | 14 |
uid motion | 14 |
statistical difference | 14 |
health board | 14 |
commonest cause | 14 |
participants underwent | 14 |
long term | 14 |
fvc ratio | 14 |
referral centres | 14 |
rage expression | 14 |
positive contacts | 14 |
regional patients | 14 |
sv transcripts | 14 |
healthy ageing | 14 |
cxcl release | 14 |
fi breoptic | 14 |
rst child | 14 |
uence expression | 14 |
clinical diagnosis | 14 |
clinical parameters | 14 |
medicine trainees | 14 |
chest wall | 14 |
cant relationship | 14 |
ndings suggest | 14 |
cpap clinic | 14 |
high proportion | 14 |
oxygen desaturation | 14 |
therapeutic targeting | 14 |
protein deposition | 14 |
using molecular | 14 |
vibrating membrane | 14 |
diagnostic procedure | 14 |
culture protocol | 14 |
intercostal catheter | 14 |
exacerbation plans | 14 |
sleep apnoea | 14 |
shorter latency | 14 |
parapneumonic effusions | 14 |
likely due | 14 |
medrxiv preprint | 14 |
children requiring | 14 |
invasive ct | 14 |
bed days | 14 |
pilot cross | 14 |
inpatient prescriptions | 14 |
care services | 14 |
mixed granulocytic | 14 |
transverse airway | 14 |
abnormal glucose | 14 |
sibling controls | 14 |
exercise capacity | 14 |
frequent upper | 14 |
auckland city | 14 |
day following | 14 |
particle number | 14 |
tropical countries | 14 |
high incidence | 14 |
patients cleared | 14 |
receptor subtype | 14 |
ventilation perfusion | 14 |
interval training | 14 |
slice ct | 14 |
mitochondrial dysfunction | 14 |
radiological fi | 14 |
higher numbers | 14 |
smoke extract | 14 |
membrane nebulizers | 14 |
cultured airway | 14 |
airway wall | 14 |
surfactant era | 14 |
weekly intra | 14 |
mean fl | 14 |
exercise consisted | 14 |
walk distance | 14 |
expenditure activities | 14 |
pig model | 14 |
based tasmanian | 14 |
graft iet | 14 |
response using | 14 |
subjects undergoing | 14 |
english hospitals | 14 |
current smokers | 14 |
exercised twice | 14 |
airway compliance | 14 |
immunocompromised hosts | 14 |
using multiparameter | 14 |
support nil | 14 |
current service | 14 |
cytokines determined | 14 |
mini kit | 14 |
management algorithm | 14 |
conclusion non | 14 |
tissue disease | 14 |
cant risk | 14 |
pa dnase | 14 |
medical wards | 14 |
respiratory picornaviruses | 14 |
carv infection | 14 |
cant haemoptysis | 14 |
fat intake | 14 |
including device | 14 |
slice computerized | 14 |
colistin side | 14 |
cytokine responses | 14 |
airway segments | 14 |
patients infected | 14 |
venous access | 14 |
use cpap | 14 |
ar eczema | 14 |
resonant frequency | 14 |
confidence interval | 14 |
device technique | 14 |
tract samples | 14 |
collected included | 14 |
pulmonary infection | 14 |
monitoring response | 14 |
computerized tomography | 14 |
versus monocytes | 14 |
primer pair | 14 |
respiratory pathogen | 14 |
trend towards | 14 |
tertiary referral | 14 |
methods data | 14 |
gold standard | 14 |
may vary | 14 |
requiring emergency | 14 |
decreased signifi | 14 |
district health | 14 |
larynx quantifi | 14 |
bacterial infection | 14 |
key macrophage | 14 |
right caudal | 14 |
case review | 14 |
nitrogen washout | 14 |
ultrasound service | 14 |
alfred niv | 14 |
severe lower | 14 |
indigenous status | 14 |
medical ward | 14 |
large pneumothorax | 14 |
total ige | 14 |
medication charts | 14 |
sequence data | 14 |
serotype information | 14 |
children years | 14 |
rage polymorphisms | 14 |
wheezing illnesses | 14 |
copd may | 14 |
human bronchi | 14 |
patients showed | 14 |
asymptomatic infections | 14 |
cantly increased | 14 |
neutralising antibody | 14 |
whilst nasal | 14 |
commencing cpap | 14 |
well tolerated | 14 |
icc insertion | 14 |
education program | 14 |
cancer models | 14 |
underwent lung | 14 |
aberrant activation | 14 |
ed frequent | 14 |
increased graft | 14 |
pa isolates | 14 |
imaging technique | 14 |
smear positive | 14 |
hrv indices | 14 |
normal speeds | 14 |
pulse rate | 14 |
dietetic review | 14 |
intracellular cytokines | 14 |
mask sampler | 14 |
molecular characterization | 14 |
ux symptoms | 14 |
grant support | 14 |
icc drainage | 14 |
foundation wa | 14 |
studies used | 14 |
mechanisms may | 14 |
related quality | 14 |
identify sp | 14 |
rage ligands | 14 |
transcription polymerase | 14 |
hour prior | 14 |
signed ranks | 14 |
nal pressure | 14 |
chronic infl | 14 |
infectious cough | 14 |
cytometric bead | 14 |
amplifi ed | 14 |
optical density | 14 |
dysfunction may | 14 |
conducting airways | 14 |
uncommon cause | 14 |
ed mantoux | 14 |
exercise sessions | 14 |
ecm proteins | 14 |
large bore | 14 |
tuberculosis infection | 14 |
lagged symptom | 14 |
density gradient | 14 |
hrv sequences | 14 |
inpatients treated | 14 |
pandemic proportion | 14 |
nebulized colistin | 14 |
mean scores | 14 |
insertion details | 14 |
followed since | 14 |
phagocytose apoptotic | 14 |
steps counted | 14 |
cant reduction | 14 |
respiratory paediatrician | 14 |
clinical follow | 14 |
pmh ed | 14 |
lung capacity | 14 |
speech therapy | 14 |
multiple breath | 14 |
ecm protein | 14 |
lung transplantation | 14 |
study group | 14 |
extracellular matrix | 14 |
di depends | 14 |
nhmrc australia | 14 |
age cohorts | 14 |
isaac phase | 14 |
high levels | 14 |
lumbar spine | 14 |
walk test | 14 |
mice exposed | 14 |
uenza infection | 14 |
reported current | 14 |
bronchodilator fev | 14 |
degrading enzymes | 14 |
underwent bronchoscopy | 14 |
excessive narrowing | 14 |
including hrv | 14 |
potentially life | 14 |
identified human | 14 |
medical care | 14 |
mantoux positive | 14 |
infl iximab | 14 |
cell lysates | 14 |
hospital attendance | 14 |
proven lrti | 14 |
genetic clustering | 14 |
pmh foundation | 14 |
vq scans | 14 |
macrophage phagocytosis | 14 |
exercise training | 14 |
viral titre | 14 |
nonatopic asthma | 14 |
particularly indigenous | 14 |
systemic levels | 14 |
shared bongs | 14 |
estimate asm | 14 |
icc treatment | 14 |
seasonal influenza | 14 |
gmf increased | 14 |
nervous system | 14 |
foreign bodies | 14 |
connective tissue | 14 |
seldinger icc | 14 |
adelaide hospital | 14 |
lung lobes | 14 |
methods adult | 14 |
lung challenges | 14 |
large pneumothoraces | 14 |
increased clsecretion | 14 |
pack furniture | 14 |
ventilatory response | 14 |
viral infectivity | 13 |
may increase | 13 |
review board | 13 |
family picornaviridae | 13 |
isolates collected | 13 |
adult volunteers | 13 |
protective effect | 13 |
aspergillus fumigatus | 13 |
increased levels | 13 |
among adults | 13 |
pairwise nucleotide | 13 |
linear regression | 13 |
bronchial epithelium | 13 |
antiviral drugs | 13 |
high level | 13 |
children human | 13 |
allergen sensitization | 13 |
induced aris | 13 |
disease virus | 13 |
neutralizing antibody | 13 |
aged months | 13 |
two studies | 13 |
acquired respiratory | 13 |
mg kg | 13 |
crystal structure | 13 |
community study | 13 |
household members | 13 |
multiple infections | 13 |
rhinovirus detection | 13 |
receptor group | 13 |
reduced risk | 13 |
platelet count | 13 |
institutional review | 13 |
nitrogen dioxide | 13 |
independent risk | 13 |
urban areas | 13 |
wind velocity | 13 |
antiviral compounds | 13 |
virtual screening | 13 |
southern brazil | 13 |
chest radiographs | 13 |
observational studies | 13 |
inclusion criteria | 13 |
national health | 13 |
experimentally infected | 13 |
year study | 13 |
five years | 13 |
different concentrations | 13 |
aged years | 13 |
infected children | 13 |
relatively high | 13 |
significant association | 13 |
previously undetected | 13 |
patients hospitalized | 13 |
expiratory wheezing | 13 |
vero cells | 13 |
children younger | 13 |
medical research | 13 |
within hours | 13 |
molecular diagnostics | 13 |
positive group | 13 |
nasal swab | 13 |
new respiratory | 13 |
epithelial damage | 13 |
frequent detection | 13 |
chart review | 13 |
resequencing microarray | 13 |
tract viral | 13 |
relative risk | 13 |
intervention group | 13 |
viral exacerbations | 13 |
asymptomatic infection | 13 |
fi nding | 13 |
sequence identity | 13 |
commercially available | 13 |
cases per | 13 |
iii ifns | 13 |
using conventional | 13 |
one hundred | 13 |
linked immunosorbent | 13 |
whole genome | 13 |
average temperature | 13 |
airway resistance | 13 |
frequent cause | 13 |
including respiratory | 13 |
among hrv | 13 |
iga memory | 13 |
randomised controlled | 13 |
illness severity | 13 |
diverse group | 13 |
cytokine production | 13 |
asthma among | 13 |
cigarette smoking | 13 |
viruses among | 13 |
unrecognized human | 13 |
longitudinal study | 13 |
base calls | 13 |
hrv activity | 13 |
specific viral | 13 |
requiring hospitalization | 13 |
time nasba | 13 |
three times | 13 |
health organization | 13 |
negative controls | 13 |
virus families | 13 |
pcr primer | 12 |
children respiratory | 12 |
antiviral responses | 12 |
undetected hrv | 12 |
dis doi | 12 |
arg gly | 12 |
starting material | 12 |
cause severe | 12 |
viral clearance | 12 |
positive predictive | 12 |
high degree | 12 |
virus negative | 12 |
cluster analysis | 12 |
infect dis | 12 |
developing asthma | 12 |
younger children | 12 |
hrv genotypes | 12 |
young infants | 12 |
nasopharyngeal swabs | 12 |
accurate diagnosis | 12 |
significantly greater | 12 |
major risk | 12 |
significantly reduced | 12 |
treatment strategies | 12 |
studies will | 12 |
immune function | 12 |
results also | 12 |
international committee | 12 |
average daily | 12 |
mycoplasma pneumoniae | 12 |
maternal smoking | 12 |
gene polymorphisms | 12 |
neutralizing antibodies | 12 |
disease associated | 12 |
east respiratory | 12 |
increasing number | 12 |
incubation period | 12 |
infection rate | 12 |
dependent manner | 12 |
end probe | 12 |
community respiratory | 12 |
commonly detected | 12 |
early detection | 12 |
hrv genome | 12 |
mrna levels | 12 |
probably representing | 12 |
atopic characteristics | 12 |
infection occurred | 12 |
asthma compared | 12 |
causes asthma | 12 |
studies showed | 12 |
reported asthma | 12 |
binding compounds | 12 |
initial infection | 12 |
patients treated | 12 |
viral gastroenteritis | 12 |
heart score | 12 |
corticosteroid therapy | 12 |
rapid diagnosis | 12 |
viral illness | 12 |
demographic characteristics | 12 |
frequently associated | 12 |
rna infectivity | 12 |
influenza infection | 12 |
subsequent development | 12 |
cell line | 12 |
kg day | 12 |
infections due | 12 |
elderly persons | 12 |
th responses | 12 |
allergen avoidance | 12 |
hrv viral | 12 |
patients died | 12 |
study conducted | 12 |
severe rsv | 12 |
meteorological factors | 12 |
picornavirus infections | 12 |
care workers | 12 |
variable selection | 12 |
differentially expressed | 12 |
monoclonal antibodies | 12 |
based cohort | 12 |
may affect | 12 |
human epithelial | 12 |
day care | 12 |
negative results | 12 |
analysis using | 12 |
mouse models | 12 |
randomized trial | 12 |
human tracheal | 12 |
associated hospitalizations | 12 |
nasopharyngeal aspirate | 12 |
longer duration | 12 |
control groups | 12 |
phase ii | 12 |
hrv serotype | 12 |
dynamic range | 12 |
hrv single | 12 |
like particles | 12 |
suffi cient | 12 |
novel coronavirus | 12 |
respiratory epithelium | 12 |
per cent | 12 |
occupational asthma | 12 |
genome characterization | 12 |
asthma risk | 12 |
lactiflora root | 12 |
novel rhinovirus | 12 |
wheezy bronchitis | 12 |
children without | 12 |
multiple viral | 12 |
previously published | 12 |
also reduced | 12 |
antigen detection | 12 |
two hundred | 12 |
time point | 12 |
lung injury | 12 |
clinical use | 12 |
viral agents | 12 |
blood cultures | 12 |
based methods | 12 |
central role | 12 |
aged less | 12 |
uenza virus | 12 |
natural infection | 12 |
two different | 12 |
cell numbers | 11 |
genetic variability | 11 |
mild asthma | 11 |
positive correlation | 11 |
rhinovirus transmission | 11 |
antibody production | 11 |
cell types | 11 |
two doses | 11 |
randomly selected | 11 |
hospitalized wheezing | 11 |
enteric viruses | 11 |
lbw infants | 11 |
single infection | 11 |
viral shedding | 11 |
cultures treated | 11 |
coronavirus infections | 11 |
early treatment | 11 |
patients presented | 11 |
subsequent asthma | 11 |
nasopharyngeal washings | 11 |
authors declare | 11 |
within days | 11 |
increased expression | 11 |
within families | 11 |
allergic asthma | 11 |
viral protein | 11 |
rhinovirus outbreak | 11 |
asthma therapy | 11 |
molecular evolution | 11 |
chronic bronchitis | 11 |
following infection | 11 |
steroid resistance | 11 |
wheezing rhinovirus | 11 |
influenza vaccination | 11 |
iga antibody | 11 |
generation sequencing | 11 |
immune activation | 11 |
asthma education | 11 |
two patients | 11 |
tertiary care | 11 |
inflammatory cytokines | 11 |
fold higher | 11 |
chronic pulmonary | 11 |
without respiratory | 11 |
molecular evolutionary | 11 |
confounding factors | 11 |
antibody levels | 11 |
different serotypes | 11 |
statistical significance | 11 |
active smoking | 11 |
may represent | 11 |
asthmatic individuals | 11 |
samples using | 11 |
common viral | 11 |
tracheal epithelial | 11 |
syncytial viruses | 11 |
increasingly recognized | 11 |
seeplex rv | 11 |
three hrv | 11 |
adult asthma | 11 |
reduction algorithms | 11 |
older adults | 11 |
first time | 11 |
school children | 11 |
atopic disease | 11 |
hrv lrti | 11 |
phylogenetic trees | 11 |
illness episode | 11 |
care units | 11 |
induced allergic | 11 |
mean numbers | 11 |
experimental animals | 11 |
infection induces | 11 |
stepwise variable | 11 |
time period | 11 |
induced il | 11 |
copies reaction | 11 |
molecular diagnosis | 11 |
ar arg | 11 |
previous work | 11 |
severe complications | 11 |
mixed viral | 11 |
hrv detections | 11 |
acute upper | 11 |
picornavirus infection | 11 |
patient population | 11 |
breast feeding | 11 |
daily activities | 11 |
also shown | 11 |
tested negative | 11 |
per day | 11 |
acute expiratory | 11 |
diagnostic criteria | 11 |
common chronic | 11 |
children enrolled | 11 |
systemic lymphoid | 11 |
least two | 11 |
receptor binding | 11 |
complete nucleotide | 11 |
iii interferon | 11 |
gel electrophoresis | 11 |
human parvovirus | 11 |
genetic analysis | 11 |
intestinal lamina | 11 |
clinical assessment | 11 |
greater severity | 11 |
clinical studies | 11 |
genomic dna | 11 |
dna viruses | 11 |
negative samples | 11 |
random hexamer | 11 |
virol doi | 11 |
investigated whether | 11 |
excessive airway | 11 |
additional studies | 11 |
detect respiratory | 11 |
communityacquired pneumonia | 11 |
strains may | 11 |
signaling pathways | 11 |
supplemental material | 11 |
fi nd | 11 |
human studies | 11 |
health effects | 11 |
molecular level | 11 |
mainly due | 11 |
peer review | 11 |
incidence rate | 11 |
coronavirus nl | 11 |
molecular mechanisms | 11 |
multivariable model | 10 |
ng ml | 10 |
clinical management | 10 |
negative control | 10 |
disease exacerbations | 10 |
pulmonary exacerbations | 10 |
different types | 10 |
new england | 10 |
vp coding | 10 |
tested using | 10 |
calculated using | 10 |
naturally acquired | 10 |
antibody response | 10 |
confi rm | 10 |
cells per | 10 |
neutrophilic airway | 10 |
whose mothers | 10 |
advisory committee | 10 |
virus load | 10 |
breaths min | 10 |
hospital serdang | 10 |
protein synthesis | 10 |
surveillance system | 10 |
epidemiological data | 10 |
cells expressing | 10 |
nasal secretion | 10 |
phase three | 10 |
epidemiological study | 10 |
muscle cells | 10 |
clinical significance | 10 |
induced ari | 10 |
recurrent exacerbations | 10 |
respiratory complications | 10 |
one third | 10 |
cell memory | 10 |
host defense | 10 |
experimental studies | 10 |
preterm infants | 10 |
heart disease | 10 |
cant association | 10 |
moderately severe | 10 |
infections often | 10 |
bacterial colonization | 10 |
different virus | 10 |
previously known | 10 |
usually associated | 10 |
iii interferons | 10 |
children clinical | 10 |
environmental tobacco | 10 |
infections caused | 10 |
defi nition | 10 |
diagnosed viral | 10 |
total rna | 10 |
infection among | 10 |
tissue damage | 10 |
molecular features | 10 |
supplemental oxygen | 10 |
sensitive molecular | 10 |
known human | 10 |
major pathogen | 10 |
among patients | 10 |
human immunodeficiency | 10 |
serum antibody | 10 |
induced lrtis | 10 |
either rsv | 10 |
growth factor | 10 |
culture techniques | 10 |
relative odds | 10 |
high number | 10 |
selective pressure | 10 |
despite extensive | 10 |
bronchial lavage | 10 |
higher risk | 10 |
less often | 10 |
biopsy samples | 10 |
affected children | 10 |
viral induced | 10 |
gastrointestinal tract | 10 |
will provide | 10 |
eosinophil count | 10 |
patients required | 10 |
hrv transmission | 10 |
larger sample | 10 |
human meta | 10 |
bootstrap values | 10 |
clinical care | 10 |
novel target | 10 |
diagnostic accuracy | 10 |
categorical variables | 10 |
common viruses | 10 |
nasal spray | 10 |
daily life | 10 |
collaborative report | 10 |
study demonstrates | 10 |
asthma outcomes | 10 |
familial predisposition | 10 |
cell activity | 10 |
induced airway | 10 |
like strains | 10 |
gastrointestinal symptoms | 10 |
late stage | 10 |
infants born | 10 |
young adult | 10 |
reaction detection | 10 |
immunocompetent patients | 10 |
single hrv | 10 |
infections cause | 10 |
best hit | 10 |
household transmission | 10 |
matrix metalloproteinase | 10 |
cellular senescence | 10 |
winter season | 10 |
nhanes iii | 10 |
human adenovirus | 10 |
prick test | 10 |
nasal mucosa | 10 |
phylogenetic analyses | 10 |
influenza season | 10 |
enterovirus infection | 10 |
animal studies | 10 |
based assays | 10 |
intestinal lymphoid | 10 |
cohort followed | 10 |
rhinovirus genus | 10 |
outcome variable | 10 |
chest radiograph | 10 |
viral proteins | 10 |
weeks gestation | 10 |
bocavirus infection | 10 |
vp sequencing | 10 |
viral life | 10 |
cytokine levels | 10 |
drug treatment | 10 |
healthy individuals | 10 |
methacholine challenge | 10 |
specific antibody | 10 |
also used | 10 |
small airway | 10 |
structural features | 10 |
time course | 10 |
studies indicated | 10 |
previously well | 10 |
case report | 10 |
mean optical | 10 |
masstag polymerase | 10 |
remains unknown | 10 |
th cells | 10 |
recombination events | 10 |
reference laboratory | 10 |
tropical areas | 10 |
viral types | 10 |
participants reported | 10 |
per patient | 10 |
effi cacious | 10 |
paediatric respiratory | 10 |
viral cause | 10 |
expiratory flow | 10 |
lavage samples | 10 |
sole hrv | 10 |
days prior | 10 |
statistical analyses | 10 |
distress syndrome | 10 |
children presenting | 10 |
additional respiratory | 10 |
transmission events | 10 |
different respiratory | 10 |
among young | 10 |
inoculated onto | 10 |
genetically diverse | 10 |
immunodeficiency virus | 10 |
masstag pcr | 10 |
joining method | 10 |
longitudinal cohort | 10 |
peak expiratory | 10 |
bacterial culture | 10 |
genus enterovirus | 10 |
major site | 10 |
severe ari | 10 |
mortality associated | 10 |
reference strain | 10 |
airway hyperreactivity | 10 |
lrti events | 10 |
may protect | 10 |
biological evaluation | 10 |
newly discovered | 10 |
predict subsequent | 10 |
host innate | 10 |
identify viruses | 10 |
serum albumin | 10 |
picornaviridae family | 10 |
ohio hela | 10 |
well plates | 10 |
temperate climates | 10 |
stool samples | 10 |
children rhinovirus | 10 |
outbreak orphanage | 10 |
pandemic influenza | 10 |
different time | 9 |
van der | 9 |
data including | 9 |
culture medium | 9 |
incidence rates | 9 |
seasonal pattern | 9 |
mice infected | 9 |
patient management | 9 |
protective role | 9 |
infants suffering | 9 |
reference sequences | 9 |
thai children | 9 |
hrv disease | 9 |
little data | 9 |
study using | 9 |
sequence diversity | 9 |
known hrv | 9 |
symptomatic infection | 9 |
skin prick | 9 |
time polymerase | 9 |
related morbidity | 9 |
sars patients | 9 |
asthma prevention | 9 |
infection severity | 9 |
reduced cell | 9 |
pyrrolidine dithiocarbamate | 9 |
children using | 9 |
viral antigen | 9 |
combination therapy | 9 |
culture negative | 9 |
american ginseng | 9 |
inactivated vaccine | 9 |
never smoked | 9 |
fl uids | 9 |
hrv antigen | 9 |
bacterial respiratory | 9 |
function abnormalities | 9 |
limited value | 9 |
using human | 9 |
infant respiratory | 9 |
patient characteristics | 9 |
symptoms indicating | 9 |
hrv may | 9 |
rotavirus vaccine | 9 |
retrospective analysis | 9 |
ammatory markers | 9 |
results compared | 9 |
induced lung | 9 |
using nasal | 9 |
year prospective | 9 |
ca subspecies | 9 |
specific antibodies | 9 |
infectious material | 9 |
investigated using | 9 |
strong association | 9 |
amplicon sequencing | 9 |
term effects | 9 |
interbeat interval | 9 |
new human | 9 |
hrv illness | 9 |
predict asthma | 9 |
targeted therapy | 9 |
airway epithelia | 9 |
low incidence | 9 |
low concentrations | 9 |
respiratory outbreaks | 9 |
autonomic nervous | 9 |
growing body | 9 |
mitochondrial function | 9 |
one child | 9 |
normal range | 9 |
systematic reviews | 9 |
host immunity | 9 |
regulatory mechanisms | 9 |
binding site | 9 |
recently published | 9 |
tight junction | 9 |
single viral | 9 |
often used | 9 |
median number | 9 |
protective mechanism | 9 |
accession numbers | 9 |
primary diagnosis | 9 |
asthmatic bronchial | 9 |
industrial population | 9 |
patients without | 9 |
putative new | 9 |
samples obtained | 9 |
possible lrti | 9 |
expired volume | 9 |
viruses identified | 9 |
severe exacerbations | 9 |
consecutive days | 9 |
including patients | 9 |
management program | 9 |
function data | 9 |
low rate | 9 |
needle aspiration | 9 |
infected cell | 9 |
geographic distribution | 9 |
acid sequences | 9 |
vp regions | 9 |
pathways involved | 9 |
standard hrv | 9 |
wide variety | 9 |
sirt activator | 9 |
based design | 9 |
small intestinal | 9 |
low density | 9 |
healthy adults | 9 |
gender differences | 9 |
underlying conditions | 9 |
validated using | 9 |
grant number | 9 |
one day | 9 |
higher threshold | 9 |
global initiative | 9 |
pneumonia caused | 9 |
nested multiplex | 9 |
possible role | 9 |
health services | 9 |
highest levels | 9 |
cultures without | 9 |
tree reconstruction | 9 |
early morning | 9 |
clinical decision | 9 |
many people | 9 |
also reported | 9 |
ethidium bromide | 9 |
rotavirus infections | 9 |
greater increase | 9 |
routine use | 9 |
severe clinical | 9 |
data suggests | 9 |
rank test | 9 |
virus interference | 9 |
using rt | 9 |
nk cell | 9 |
new species | 9 |
flu infections | 9 |
surrounding areas | 9 |
less frequent | 9 |
studies demonstrated | 9 |
sars coronavirus | 9 |
hrv strain | 9 |
table i | 9 |
genetics analysis | 9 |
refl ects | 9 |
symptoms associated | 9 |
additional file | 9 |
prototype sequence | 9 |
molecular screening | 9 |
remain poorly | 9 |
health outcomes | 9 |
influenza immunization | 9 |
custom software | 9 |
generally mild | 9 |
acute myocardial | 9 |
protein vp | 9 |
two decades | 9 |
response slope | 9 |
diagnostic methods | 9 |
geographic region | 9 |
within week | 9 |
required hospital | 9 |
antiviral signalling | 9 |
developed countries | 9 |
dual infection | 9 |
transcriptional activity | 9 |
evolutionary genetics | 9 |
infancy predict | 9 |
one virus | 9 |
standard pcr | 9 |
sputum induction | 9 |
coding sequences | 9 |
gastrointestinal viruses | 9 |
south wales | 9 |
coronavirus infection | 9 |
rna extracted | 9 |
proinflammatory cytokines | 9 |
life technologies | 9 |
specimens obtained | 9 |
contributing factor | 9 |
matched control | 9 |
low dose | 9 |
signifi cance | 9 |
infection rates | 9 |
lockdown period | 9 |
qiaamp viral | 9 |
hand washing | 9 |
foster city | 9 |
relatively low | 9 |
hrv genomes | 9 |
new south | 9 |
offi ce | 9 |
lambda subtypes | 9 |
direct elisa | 9 |
conclusion hrv | 9 |
increased rate | 9 |
positively correlated | 9 |
ned using | 9 |
conserved among | 9 |
scoring system | 9 |
differential diagnosis | 9 |
fold dilutions | 9 |
patients diagnosed | 9 |
coding sequence | 9 |
incidence curves | 9 |
group patients | 9 |
time nucleic | 9 |
living within | 9 |
southern hemisphere | 9 |
investigate whether | 9 |
genetic predisposition | 9 |
transport medium | 9 |
bronchial washings | 9 |
asthma remains | 9 |
molecular beacon | 9 |
remained stable | 9 |
hyperimmune serum | 9 |
medical attention | 9 |
single infections | 9 |
enterovirus rna | 9 |
high morbidity | 9 |
study carried | 9 |
respiratory rate | 9 |
outpatient clinics | 9 |
emergency room | 9 |
transcription factors | 9 |
specifi cally | 9 |
hrv induced | 9 |
lambda levels | 9 |
viral stocks | 9 |
positive subjects | 9 |
therapeutic approaches | 9 |
cardiac events | 9 |
adrenergic receptor | 9 |
clinical context | 9 |
oral pleconaril | 9 |
study design | 9 |
health service | 9 |
clinical testing | 9 |
viral pneumonia | 9 |
analysis algorithm | 9 |
close contact | 9 |
random sample | 9 |
human bronchial | 9 |
antiviral immunity | 9 |
increased use | 9 |
within hrv | 9 |
subsequent childhood | 9 |
three multiplex | 9 |
regular exercise | 9 |
new approach | 9 |
without affecting | 9 |
following challenge | 9 |
illness caused | 9 |
classifi cation | 9 |
ari cases | 9 |
decreased risk | 9 |
negative groups | 9 |
streptococcus pyogenes | 9 |
samples taken | 9 |
mrc cells | 9 |
human disease | 9 |
related severe | 9 |
hrv groups | 9 |
less frequently | 9 |
ct scans | 9 |
critical importance | 9 |
antimicrobial therapy | 9 |
adaptive immune | 9 |
cell protein | 9 |
cold viruses | 9 |
bronchial biopsies | 9 |
routine diagnostic | 9 |
autonomic function | 9 |
human metapneumoviruses | 9 |
twofold increase | 9 |
human volunteers | 9 |
negatively associated | 9 |
control program | 9 |
sequence divergence | 9 |
university hospital | 9 |
recent evidence | 9 |
life predict | 9 |
secreting cell | 9 |
data sets | 9 |
commonly found | 9 |
volatile organic | 8 |
participants received | 8 |
additive effect | 8 |
using mouse | 8 |
often co | 8 |
body weight | 8 |
normal fl | 8 |
rcv compared | 8 |
study reports | 8 |
hajj pilgrims | 8 |
buffered saline | 8 |
irreversible human | 8 |
different species | 8 |
japanese children | 8 |
mean pressure | 8 |
considered mostly | 8 |
findings suggest | 8 |
will improve | 8 |
undergoing diagnostic | 8 |
adults aged | 8 |
become available | 8 |
mucus hypersecretion | 8 |
homing receptor | 8 |
retrospectively reviewed | 8 |
commonly affected | 8 |
viral species | 8 |
crystal structures | 8 |
induced rhinovirus | 8 |
variable among | 8 |
molecular surveillance | 8 |
either hrv | 8 |
studies provide | 8 |
improved outcomes | 8 |
normal group | 8 |
pcr kit | 8 |
specific igg | 8 |
infants hospitalized | 8 |
viral titers | 8 |
requiring hospital | 8 |
hierarchical cluster | 8 |
presenting symptoms | 8 |
sputum eosinophils | 8 |
hunter hospital | 8 |
major symptoms | 8 |
care system | 8 |
position statement | 8 |
aged days | 8 |
whether changes | 8 |